Total trials
574
Active
78
Phase 3
50
Total enrollment
1,810,356
Pipeline matrix
Showing 40 of 56 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Aspirin | — | — | — | — | — | 5 | |
| Treatment | — | — | — | — | — | 2 | |
| Cilostazol | — | — | — | — | — | 5 | |
| Warfarin | — | — | — | — | 3 | ||
| clopidogrel | — | — | — | — | — | 2 | |
| BPaL(M) regimen | — | — | — | — | — | 1 | |
| TDM-based infliximab intravenous therapy | — | — | — | — | — | 1 | |
| Standard infliximab intravenous therapy | — | — | — | — | — | 1 | |
| Inhaled Nitric Oxide | — | — | — | — | — | 1 | |
| Stop group | — | — | — | — | — | 1 | |
| Vitamin K antagonist | — | — | — | — | — | 1 | |
| Pitavastatin 4mg and ezetimibe 10mg, taken once daily | — | — | — | — | — | 1 | |
| Pitavastatin 2 mg with aspirin 100 mg, taken once daily. | — | — | — | — | — | 1 | |
| Capecitabine | — | — | — | — | 3 | ||
| Cytarabine | — | — | — | — | 2 | ||
| Docetaxel and capecitabine and oxaliplatin | — | — | — | — | — | 1 | |
| capecitabine and oxaliplatin | — | — | — | — | — | 1 | |
| Tislelizumab | — | — | — | — | — | 1 | |
| High dose Cytarabine | — | — | — | — | — | 1 | |
| Hign dose Daunorubicin | — | — | — | — | — | 1 | |
| Ferinject | — | — | — | — | — | 1 | |
| High-dose trivalent inactivated influenza vaccine | — | — | — | — | — | 1 | |
| MF59-adjuvanted quadrivalent inactivated influenza vaccine | — | — | — | — | — | 1 | |
| Standard-dose trivalent inactivated influenza vaccine | — | — | — | — | — | 1 | |
| Enavogliflozin | — | — | — | — | — | 1 | |
| Lenvatinib | — | — | — | — | — | 4 | |
| Cyclophosphamide | — | — | — | — | — | 8 | |
| Imatinib Mesylate | — | — | — | — | — | 4 | |
| Oxaliplatin | — | — | — | — | — | 3 | |
| Docetaxel | — | — | — | — | — | 2 | |
| S-1 | — | — | — | — | — | 2 | |
| Durvalumab | — | — | — | — | — | 2 | |
| Temozolomide | — | — | — | — | 2 | ||
| zolbetuximab | — | — | — | — | — | 1 | |
| Olaparib | — | — | — | — | — | 1 | |
| Platinum Based Chemotherapy | — | — | — | — | — | 1 | |
| Rivoceranib Mesylate, Paclitaxel | — | — | — | — | — | 1 | |
| mFOLFIRINOX | — | — | — | — | — | 1 | |
| irpagratinib | — | — | — | — | — | 1 | |
| Docetaxel injection, oxaliplatin, S-1 | — | — | — | — | — | 1 |
16 more active programs hidden
Next readouts
- 2023-06-30
- 2024-08-19
- 2025-01-23
- 2025-05-12
- 2025-06-27
- 2025-07-30
- 2025-12-30
- 2026-03
- 2026-06-30
- 2026-08-01
Top conditions
- Hepatocellular Carcinoma15
- Gastrointestinal Stromal Tumors13
- Gastric Cancer11
- Prostate Cancer10
- Cervical Cancer9
- Breast Cancer9
- Healthy9
- Leukemia8
Frequently asked questions about Asan Medical Center
- How many clinical trials does Asan Medical Center have on ClinicalTrials.gov?
- Asan Medical Center is listed as the lead sponsor on 574 clinical trials in ClinicalTrials.gov, 78 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Asan Medical Center's trials are in Phase 3?
- 50 of Asan Medical Center's trials are in Phase 3, spread across 56 active drug programs.
- What therapeutic areas does Asan Medical Center focus on?
- Asan Medical Center's most-studied conditions on ClinicalTrials.gov are Hepatocellular Carcinoma, Gastrointestinal Stromal Tumors, Gastric Cancer, Prostate Cancer, Cervical Cancer.
- When are Asan Medical Center's next clinical trial readouts?
- Asan Medical Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer”, expected around 2023-06-30.